(Q53184931)

English

Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.

scientific article published on 20 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

author name string

Aurora Sainz-Esteban

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Vikas Prasad

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Christiane Schuchardt

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Carolin Zachert

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

José Manuel Carril

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Richard P Baum

6

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

publication date

20 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

European Journal of Nuclear Medicine and Molecular Imaging

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

39

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

501-511

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

Gastroenteropancreatic neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Peptide receptors as molecular targets for cancer diagnosis and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Neuroendocrine tumors. Peptide receptor radionuclide therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

68Ga-labelled DOTA-derivatised peptide ligands

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Imaging of neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Incremental value of 111-in pentetreotide SPECT/CT fusion imaging of neuroendocrine tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Hybrid imaging (SPECT/CT and PET/CT)--improving the diagnostic accuracy of functional/metabolic and anatomic imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT

1 reference

https://api.crossref.org/works/10.1007%2FS00259-011-2003-X

21 January 2018

Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Processing of generator-produced 68Ga for medical application.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interesting image. Pancreatic neuroendocrine tumor with involvement of the inferior mesenteric vein diagnosed by Ga-68 DOTA-TATE PET/CT

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor PET/CT imaging of neuroendocrine tumors.

1 reference

https://pubmed.ncbi.nlm.nih.gov/22183108

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00259-011-2003-X

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/22183108

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53184931&oldid=2212022602"